Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have received an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $34.25.

A number of analysts have recently commented on the stock. Robert W. Baird boosted their price objective on shares of Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Denali Therapeutics in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Monday, April 20th. UBS Group restated a “buy” rating on shares of Denali Therapeutics in a research note on Tuesday. Finally, HC Wainwright increased their price objective on shares of Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th.

Hedge Funds Weigh In On Denali Therapeutics

A number of large investors have recently modified their holdings of DNLI. Norges Bank acquired a new position in shares of Denali Therapeutics during the 4th quarter worth about $84,525,000. Holocene Advisors LP boosted its stake in shares of Denali Therapeutics by 677.8% during the 3rd quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock worth $45,531,000 after buying an additional 2,732,540 shares during the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Denali Therapeutics by 3,490.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock worth $35,932,000 after buying an additional 1,819,339 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Denali Therapeutics by 77.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock worth $63,329,000 after buying an additional 1,672,098 shares during the last quarter. Finally, Temasek Holdings Private Ltd boosted its stake in shares of Denali Therapeutics by 30.9% during the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after buying an additional 1,657,142 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $23.31 on Friday. The firm has a market cap of $3.70 billion, a PE ratio of -8.09 and a beta of 1.03. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 1-year low of $12.58 and a 1-year high of $24.65. The company has a fifty day moving average price of $20.02 and a 200 day moving average price of $19.54.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter last year, the business earned ($0.78) earnings per share. Research analysts predict that Denali Therapeutics will post -2.77 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.